Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

June 5, 2024

Study Completion Date

June 1, 2026

Conditions
Breast Cancer Female
Interventions
DRUG

tamoxifen, letrozole, anastrozole, or exemestane

choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist

BEHAVIORAL

Patient reported outcomes

"Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy"

Trial Locations (2)

22908

University of Virginia, Charlottesville

23298

Virginia Commonwealth University Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Shayna Showalter, MD

OTHER